Table 2.
Distribution of hormone therapy’s use among women aged over 50 years and enrolled in the eight French cohorts
| Age group (years) | Study
|
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPIDOS
|
ESTEV95
|
E3N
|
MONICA
|
OFELY
|
EVA
|
GAZEL
|
POLA
|
Global (%) | |||||||||
| N | %HTa | N | %HT | N | %HT | N | %HTa | N | %HTa | N | %HTa | N | %HTa | N | %HTa | ||
| 50–54a | – | – | 1201 | 64.6 | 15758 | 64.9 | 201 | 44.8 | 127 | 43.3 | – | – | 684 | 52.8 | – | – | 64.1 |
| 55–59 | – | – | 1575 | 53.8 | 11820 | 50.5 | 291 | 40.9 | 202 | 36.1 | – | – | 373 | 51.2 | – | – | 50.5 |
| 60–64 | – | – | – | – | 7273 | 33.8 | 325 | 19.4 | 100 | 17.0 | – | – | – | – | 333 | 18.0 | 32.3 |
| 65–69 | – | – | – | – | – | – | – | – | 61 | 4.9 | 110 | 24.5 | – | – | 371 | 4.6 | 8.7 |
| 70–74 | – | – | – | – | – | – | – | – | 89 | 0 | 250 | 14.0 | – | – | 360 | 1.4 | 5.7 |
| 75–79 | 3823 | 7.7 | – | – | – | – | – | – | 79 | 0 | 109 | 11.0 | – | – | 221 | 0.5 | 7.3 |
| 80–84 | 2573 | 6.6 | – | – | – | – | – | – | – | – | – | – | 166 | 0 | 6.2 | ||
| 85–89 | 810 | 5.9 | – | – | – | – | – | – | – | – | – | – | 5.9 | ||||
| 90+ | 134 | 2.2 | – | – | – | – | – | – | – | – | – | – | 2.2 | ||||
| Total | 7340 | 7.0 | 2776 | 58.5 | 34851 | 53.5 | 817 | 33.3 | 658 | 22.5 | 469 | 15.8 | 1057 | 52.2 | 1451 | 5.7 | 44.3 |
a
Hormone therapy.